Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2009

01-10-2009 | Breast Oncology

Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer: An Increasing Trend at a Single Institution

Authors: Natalie B. Jones, MD, John Wilson, PhD, Linda Kotur, BS, CTR, Julie Stephens, MS, William B. Farrar, MD, Doreen M. Agnese, MD

Published in: Annals of Surgical Oncology | Issue 10/2009

Login to get access

Abstract

Background

An increasing trend in the use of contralateral prophylactic mastectomy (CPM) for the treatment of unilateral breast cancer has been observed nationally. The purpose of this study was to confirm this trend and to identify differences between the groups that chose unilateral mastectomy alone or with CPM.

Methods

A prospectively maintained breast cancer database was retrospectively reviewed. Age, histologic grade, stage, education, family history, tumor receptor status, and use of immediate reconstruction were evaluated. Statistical analysis was performed by Fisher’s exact test, χ2 test, and Student’s t-test.

Results

Between 1998 and 2007, a total of 1639 women who selected UM and 201 who had UM and CPM for unilateral breast cancer were identified. An increasing trend in CPM was observed (6.5% in 1999 vs. 16.1% in 2007). The CPM group was significantly younger (mean age 47.8 vs. 55.1 years, P < .001). No difference in histologic grade was noted between the two groups; however, an increasing trend toward CPM was observed with lower-stage disease. Women with a higher educational level were more likely to have CPM (P < .001). Women with a family history of cancer were also more likely to have CPM (57% vs. 41%, P < .001). Use of reconstruction was similar between the groups (6.0% for CPM vs. 6.7% for UM, P = NS).

Conclusions

Our experience parallels the national trend of increasing use of CPM in women diagnosed with unilateral breast cancer. Women who chose to have CPM were younger, more highly educated, and more likely to have a family history of cancer.
Literature
1.
go back to reference Abrams JS, Phillips PH, Friedman MA. Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer. J Natl Cancer Inst. 1995;87:1837–45.CrossRefPubMed Abrams JS, Phillips PH, Friedman MA. Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer. J Natl Cancer Inst. 1995;87:1837–45.CrossRefPubMed
2.
go back to reference Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.CrossRefPubMed Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.CrossRefPubMed
3.
go back to reference Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a Cancer Research Network project. J Clin Oncol. 2005;23:4275–86.CrossRefPubMed Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a Cancer Research Network project. J Clin Oncol. 2005;23:4275–86.CrossRefPubMed
4.
go back to reference Robbins GF, Berg JW. Bilateral primary breast cancer, a prospective clinicopathological study. Cancer. 1964;17:1501–27.CrossRefPubMed Robbins GF, Berg JW. Bilateral primary breast cancer, a prospective clinicopathological study. Cancer. 1964;17:1501–27.CrossRefPubMed
5.
go back to reference Chaundary MA, Mills RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71:711–4.CrossRef Chaundary MA, Mills RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71:711–4.CrossRef
6.
go back to reference Rosen PP, Groshen S, Kinne DW, et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (TINOMO) and stage II (T1N1M0) patients with 20-year follow-up. Surgery. 1989;106:904–10.PubMed Rosen PP, Groshen S, Kinne DW, et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (TINOMO) and stage II (T1N1M0) patients with 20-year follow-up. Surgery. 1989;106:904–10.PubMed
7.
go back to reference Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.CrossRefPubMed Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.CrossRefPubMed
8.
go back to reference Lostumbo L, Carbine N, Wallace J, et al. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004;4:CD002748. Lostumbo L, Carbine N, Wallace J, et al. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004;4:CD002748.
9.
go back to reference Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439–45.CrossRefPubMed Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439–45.CrossRefPubMed
10.
go back to reference Wood W. Increasing use of contralateral prophylactic mastectomy: a counterintuitive trend. (The CON Perspective). Oncology. 2008;22:548–51.PubMed Wood W. Increasing use of contralateral prophylactic mastectomy: a counterintuitive trend. (The CON Perspective). Oncology. 2008;22:548–51.PubMed
11.
go back to reference Hemminki K, Jianguang J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 2007;67:868–70.CrossRefPubMed Hemminki K, Jianguang J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 2007;67:868–70.CrossRefPubMed
12.
go back to reference Verhoog LC, Brekelmans CT, Seynaerve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA 1. Lancet. 1998;351:316–21.CrossRefPubMed Verhoog LC, Brekelmans CT, Seynaerve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA 1. Lancet. 1998;351:316–21.CrossRefPubMed
13.
go back to reference Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1. and BRCA2. mutation carriers. J Clin Oncol. 2004;22:2328–35.CrossRefPubMed Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1. and BRCA2. mutation carriers. J Clin Oncol. 2004;22:2328–35.CrossRefPubMed
14.
go back to reference Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2. associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238–57.CrossRefPubMed Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2. associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238–57.CrossRefPubMed
15.
go back to reference McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–43.PubMed McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–43.PubMed
16.
go back to reference van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1. or BRCA2. mutation carriers. Br J Cancer. 2005;93:287–92.CrossRefPubMed van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1. or BRCA2. mutation carriers. Br J Cancer. 2005;93:287–92.CrossRefPubMed
17.
go back to reference Tuttle TM. Counseling breast cancer patients on contralateral prophylactic mastectomy: the physician’s role. Oncology. 2008;5:545–8. Tuttle TM. Counseling breast cancer patients on contralateral prophylactic mastectomy: the physician’s role. Oncology. 2008;5:545–8.
18.
go back to reference Nekhlyudov L, Bower M, Herrinton LJ, et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst. Monogr. 2005;35:55–60.CrossRefPubMed Nekhlyudov L, Bower M, Herrinton LJ, et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst. Monogr. 2005;35:55–60.CrossRefPubMed
19.
go back to reference Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23:7849–56.CrossRefPubMed Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23:7849–56.CrossRefPubMed
20.
go back to reference Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6:546–52.CrossRefPubMed Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6:546–52.CrossRefPubMed
21.
go back to reference Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24:1350–6.CrossRefPubMed Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24:1350–6.CrossRefPubMed
Metadata
Title
Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer: An Increasing Trend at a Single Institution
Authors
Natalie B. Jones, MD
John Wilson, PhD
Linda Kotur, BS, CTR
Julie Stephens, MS
William B. Farrar, MD
Doreen M. Agnese, MD
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0547-9

Other articles of this Issue 10/2009

Annals of Surgical Oncology 10/2009 Go to the issue